Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Bortezomib for the Treatment of Metastatic Castration-Resistant Prostate Cancer with PTEN Deletion, BORXPTEN Trial

Trial Status: active

This phase II trial tests how well bortezomib works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic), continues to grow even when the testosterone levels are at or below the castrate level (castration-resistant), and has PTEN deletion. PTEN loss is associated with aggressive features such as a high Gleason score and is regarded as a critical feature in castration-resistant prostate cancer. Bortezomib is a type of chemotherapy called a targeted therapy and belongs to a class of medicines called proteasome inhibitors. Chemotherapy drugs, such as bortezomib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Information gained from this trial may allow researchers to determine whether bortezomib can benefit patients with metastatic castration-resistant prostate cancer whose tumor has lost the PTEN gene.